Solubilization of fluasterone

Journal of Pharmaceutical Sciences

Volumn 88, Issue 10, 1999, Pages 967-969

  Zhao, Luwei ^a   Li, Ping ^a   Yalkowsky, Samuel H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BETA CYCLODEXTRIN DERIVATIVE; FLUASTERONE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG SOLUBILITY; MICELLE;

EID: 0032834728     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9901413     Document Type: Article

References (15)

1. Yalkowsky, S. H. Solubility and solubilization in aqueous media; Oxford University Press: New York, 1999.
2. Yalkowsky, S. H.; Roseman T. J. Solubilization of drugs by cosolvents. In Techniques of solubilization of drugs; Yalkowsky, S. H., Ed; Dekker: New York, 1981.
3. Yalkowsky, S. H.; Rubino, J. T. Solubilization of cosolvents 1: organic solutes in propylene glycol-water mixtures. J. Pharm. Sci. 1985, 74, 416.
4. Small, D. M. In The bile acids: chemistry, physiology and metabolism; Nair, P. P., Kritchevsky, D., Eds.; Plenum: New York, 1971; Vol. 1.
5. Pitha, J.; Milecki, J.; Fales, H.; Pannel, L.; Uekama, K. Hydroxypropyl-β-cyclodextrin: preparation and characterization: effects on solubility of drugs. Int. J. Pharm. 1986, 29, 73.
6. Uekama, K.; Otagiri, M. Cyclodextrins in therapeutic drug carrier systems. In CRC Critical reviews in therapeutic drug carrier systems; CRC Press: Boca Raton, FL, 1987.
7. Rajewski, R. A.; Stella, V. J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85, 1142.
8. Sweetana, S.; Akers, M. J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci., Technol. 1996, 5, 50.
9. Selander, D.; Curelaru, I.; Stefansson, T. Local discomfort and thrombophlebitis following intravenous injection of diazepam. Acta Anesth. Scand. 1981, 25, 516.
10. Yalkowsky, S. H.; Krzyzaniak, J. F., Ward, G. H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87, 787.
11. Powell, M. F.; Nguyen, T.; Baloian, L. Compendium of Excipients for Parenteral Formulations. PDA J. Pharm. Sci. Technol. 52, 1998, 5, 238.
12. Mesems, J. L.; Putteman, P.; Verheyen, Pharmaceutical applications of 2-hydroxypropyl-β-cyclodextrin. In New Trends in Cyclodextrins and Derivatives; Duchene, D., Ed.; Editions de Sante: Paris, 1991.
13. Brewster, M. E.; Simpkins, J. W.; Hora, M. S.; Stern, W. C.; Bodor, N. The potential use of cyclodextrins in parenteral formulations. J. Parent. Sci. Technol. 1989, 43, 231.
14. Rajewski, R. A.; Traiger, G.; Bresnahan, P.; Jaberaboansari, P.; Stella, V. J.; Thompson, D. O. Preliminary safety evaluation of paraenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci. 1995, 84, 927.
15. Okomoto, K.; Rajewski, R. A.; Uekama, K.; Jona, J. A.; Stella, V. J. The interaction of charged and uncharged drugs with neutral (HPβCD) and anionically charged (SBE7βCD) β-cyclodextrins. Pharm. Res. 1996, 13, 256.